Literature DB >> 26250566

Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.

Alexander Baraniskin1, Elena Zaslavska1, Stefanie Nöpel-Dünnebacke1, Guido Ahle1, Sabine Seidel1, Uwe Schlegel1, Wolff Schmiegel1, Stephan Hahn1, Roland Schroers1.   

Abstract

BACKGROUND: Primary central nervous system lymphomas (PCNSLs) are highly aggressive tumors. Chemotherapy has improved prognosis significantly; however, early diagnosis is crucial for effective treatment. Presently, the diagnosis of PCNSL depends on histopathology of tumor biopsies. We have previously demonstrated differential expression of microRNAs in cerebrospinal fluid (CSF) samples from patients with PCNSL. Based on promising findings about circulating U2 small nuclear RNA fragments (RNU2-1f) as novel blood-based biomarkers for pancreatic, colorectal, and lung cancer, we investigated RNU2-1f in the CSF of PCNSL patients.
METHODS: CSF was collected from patients with PCNSL (n = 72) and control patients with various neurologic disorders (n = 47). Sequential CSF samples were collected from 9 PCNSL patients. RNU2-1f levels were measured by real-time polymerase chain reaction.
RESULTS: Measurement of RNU2-1f levels in CSF enabled the differentiation of patients with PCNSL from controls with an area under the curve (AUC) of 0.909 with a sensitivity of 68.1% and a specificity of 91.4%. The diagnostic accuracy was further improved by combined determination of RNU2-1f and miR-21, resulting in AUC of 0.987 with a sensitivity of 91.7% and a specificity of 95.7%. In consecutive measurements of RNU2-1f, which were performed in 9 patients at different stages of the disease course, RNU2-1f CSF levels paralleled the course of the disease.
CONCLUSIONS: Our data suggest that the measurement of RNU2-1f detected in CSF can be used as a diagnostic marker and also as a possible marker for treatment monitoring. These promising results need to be evaluated within a larger patient cohort.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  cerebrospinal fluid (CSF); disease course; primary central nervous system lymphoma; small nuclear RNA (snRNA)

Mesh:

Substances:

Year:  2015        PMID: 26250566      PMCID: PMC4767235          DOI: 10.1093/neuonc/nov144

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  24 in total

Review 1.  Spliceosomal UsnRNP biogenesis, structure and function.

Authors:  C L Will; R Lührmann
Journal:  Curr Opin Cell Biol       Date:  2001-06       Impact factor: 8.382

2.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

Authors:  Lauren E Abrey; Tracy T Batchelor; Andrés J M Ferreri; Mary Gospodarowicz; Elisa J Pulczynski; Emanuele Zucca; Justine R Smith; Agnieszka Korfel; Carole Soussain; Lisa M DeAngelis; Edward A Neuwelt; Brian Patrick O'Neill; Eckhard Thiel; Tamara Shenkier; Fransesc Graus; Martin van den Bent; John F Seymour; Philip Poortmans; James O Armitage; Franco Cavalli
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

3.  Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group.

Authors:  Tamara N Shenkier; Jean-Yves Blay; Brian Patrick O'Neill; Philip Poortmans; Eckhard Thiel; Kristoph Jahnke; Lauren E Abrey; Edward Neuwelt; Richard Tsang; Tracy Batchelor; Nancy Harris; Andrés J M Ferreri; Maurilio Ponzoni; Peter O'Brien; James Rubenstein; Joseph M Connors
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

4.  Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.

Authors:  Alexander Baraniskin; Stefanie Nöpel-Dünnebacke; Brigitte Schumacher; Christian Gerges; Thilo Bracht; Barbara Sitek; Helmut E Meyer; Guido Gerken; Alexander Dechene; Jörg F Schlaak; Roland Schroers; Christian Pox; Wolff Schmiegel; Stephan A Hahn
Journal:  Dig Dis Sci       Date:  2014-01-31       Impact factor: 3.199

5.  Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients.

Authors:  Patrick Roth; Andreas Keller; Jörg D Hoheisel; Paula Codo; Andrea S Bauer; Christina Backes; Petra Leidinger; Eckart Meese; Eckhard Thiel; Agnieszka Korfel; Michael Weller
Journal:  Eur J Cancer       Date:  2014-12-17       Impact factor: 9.162

6.  Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma.

Authors:  Annika Juergens; Hendrik Pels; Sabine Rogowski; Klaus Fliessbach; Axel Glasmacher; Andreas Engert; Marcel Reiser; Volker Diehl; Marlies Vogt-Schaden; Gerlinde Egerer; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Udo Bode; Ulrich Herrlinger; Michael Linnebank; Martina Deckert; Rolf Fimmers; Ingo G H Schmidt-Wolf; Uwe Schlegel
Journal:  Ann Neurol       Date:  2010-02       Impact factor: 10.422

7.  Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.

Authors:  Hendrik Pels; Ingo G H Schmidt-Wolf; Axel Glasmacher; Holger Schulz; Andreas Engert; Volker Diehl; Anton Zellner; Gabriele Schackert; Heinz Reichmann; Frank Kroschinsky; Marlies Vogt-Schaden; Gerlinde Egerer; Udo Bode; Carlo Schaller; Martina Deckert; Rolf Fimmers; Christoph Helmstaedter; Aslihan Atasoy; Thomas Klockgether; Uwe Schlegel
Journal:  J Clin Oncol       Date:  2003-11-03       Impact factor: 44.544

Review 8.  MicroRNAs: critical mediators of differentiation, development and disease.

Authors:  Jeffrey M Friedman; Peter A Jones
Journal:  Swiss Med Wkly       Date:  2009-08-22       Impact factor: 2.193

9.  The transcriptional landscape of the mammalian genome.

Authors:  P Carninci; T Kasukawa; S Katayama; J Gough; M C Frith; N Maeda; R Oyama; T Ravasi; B Lenhard; C Wells; R Kodzius; K Shimokawa; V B Bajic; S E Brenner; S Batalov; A R R Forrest; M Zavolan; M J Davis; L G Wilming; V Aidinis; J E Allen; A Ambesi-Impiombato; R Apweiler; R N Aturaliya; T L Bailey; M Bansal; L Baxter; K W Beisel; T Bersano; H Bono; A M Chalk; K P Chiu; V Choudhary; A Christoffels; D R Clutterbuck; M L Crowe; E Dalla; B P Dalrymple; B de Bono; G Della Gatta; D di Bernardo; T Down; P Engstrom; M Fagiolini; G Faulkner; C F Fletcher; T Fukushima; M Furuno; S Futaki; M Gariboldi; P Georgii-Hemming; T R Gingeras; T Gojobori; R E Green; S Gustincich; M Harbers; Y Hayashi; T K Hensch; N Hirokawa; D Hill; L Huminiecki; M Iacono; K Ikeo; A Iwama; T Ishikawa; M Jakt; A Kanapin; M Katoh; Y Kawasawa; J Kelso; H Kitamura; H Kitano; G Kollias; S P T Krishnan; A Kruger; S K Kummerfeld; I V Kurochkin; L F Lareau; D Lazarevic; L Lipovich; J Liu; S Liuni; S McWilliam; M Madan Babu; M Madera; L Marchionni; H Matsuda; S Matsuzawa; H Miki; F Mignone; S Miyake; K Morris; S Mottagui-Tabar; N Mulder; N Nakano; H Nakauchi; P Ng; R Nilsson; S Nishiguchi; S Nishikawa; F Nori; O Ohara; Y Okazaki; V Orlando; K C Pang; W J Pavan; G Pavesi; G Pesole; N Petrovsky; S Piazza; J Reed; J F Reid; B Z Ring; M Ringwald; B Rost; Y Ruan; S L Salzberg; A Sandelin; C Schneider; C Schönbach; K Sekiguchi; C A M Semple; S Seno; L Sessa; Y Sheng; Y Shibata; H Shimada; K Shimada; D Silva; B Sinclair; S Sperling; E Stupka; K Sugiura; R Sultana; Y Takenaka; K Taki; K Tammoja; S L Tan; S Tang; M S Taylor; J Tegner; S A Teichmann; H R Ueda; E van Nimwegen; R Verardo; C L Wei; K Yagi; H Yamanishi; E Zabarovsky; S Zhu; A Zimmer; W Hide; C Bult; S M Grimmond; R D Teasdale; E T Liu; V Brusic; J Quackenbush; C Wahlestedt; J S Mattick; D A Hume; C Kai; D Sasaki; Y Tomaru; S Fukuda; M Kanamori-Katayama; M Suzuki; J Aoki; T Arakawa; J Iida; K Imamura; M Itoh; T Kato; H Kawaji; N Kawagashira; T Kawashima; M Kojima; S Kondo; H Konno; K Nakano; N Ninomiya; T Nishio; M Okada; C Plessy; K Shibata; T Shiraki; S Suzuki; M Tagami; K Waki; A Watahiki; Y Okamura-Oho; H Suzuki; J Kawai; Y Hayashizaki
Journal:  Science       Date:  2005-09-02       Impact factor: 47.728

10.  Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data.

Authors:  J M Ruijter; C Ramakers; W M H Hoogaars; Y Karlen; O Bakker; M J B van den Hoff; A F M Moorman
Journal:  Nucleic Acids Res       Date:  2009-02-22       Impact factor: 16.971

View more
  22 in total

1.  Truncated forms of U2 snRNA (U2-tfs) are shunted toward a novel uridylylation pathway that differs from the degradation pathway for U1-tfs.

Authors:  Hideaki Ishikawa; Yuko Nobe; Keiichi Izumikawa; Masato Taoka; Yoshio Yamauchi; Hiroshi Nakayama; Richard J Simpson; Toshiaki Isobe; Nobuhiro Takahash
Journal:  RNA Biol       Date:  2017-12-15       Impact factor: 4.652

Review 2.  Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!

Authors:  Maxime Fontanilles; Alberto Duran-Peña; Ahmed Idbaih
Journal:  Curr Neurol Neurosci Rep       Date:  2018-03-09       Impact factor: 5.081

3.  Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.

Authors:  Jens Köhler; Martin Schuler; Thomas Christoph Gauler; Stefanie Nöpel-Dünnebacke; Maike Ahrens; Andreas-Claudius Hoffmann; Stefan Kasper; Felix Nensa; Benedikt Gomez; Maria Hahnemann; Frank Breitenbuecher; Danjouma Cheufou; Filiz Özkan; Kaid Darwiche; Mathias Hoiczyk; Henning Reis; Stefan Welter; Wilfried Ernst Erich Eberhardt; Martin Eisenacher; Helmut Teschler; Georgios Stamatis; Wolff Schmiegel; Stephan Albrecht Hahn; Alexander Baraniskin
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-19       Impact factor: 4.553

Review 4.  Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?

Authors:  K Grace Ho; Christian Grommes
Journal:  Curr Opin Neurol       Date:  2019-12       Impact factor: 5.710

5.  MicroRNAs as Diagnostic Biomarkers in Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.

Authors:  Xiaohong Zheng; Parker Li; Qianqian Dong; Yihong Duan; Shoubo Yang; Zehao Cai; Feng Chen; Wenbin Li
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

Review 6.  Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study.

Authors:  Fang Bao; Jiayue Liu; Haiyang Chen; Lu Miao; Zhaochao Xu; Guixin Zhang
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575

Review 7.  Role of microRNAs in primary central nervous system lymphomas.

Authors:  Xin Yu; Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2016-03-16       Impact factor: 6.831

8.  Optic Nerve Infiltration in Primary Central Nervous System Lymphoma.

Authors:  Guido Ahle; Valérie Touitou; Nathalie Cassoux; Marie Bouyon; Catherine Humbrecht; Hélène Oesterlé; Alexander Baraniskin; Carole Soussain; Ludovic Nguyen-Them; Claude Gaultier; Khê Hoang-Xuan; Caroline Houillier
Journal:  JAMA Neurol       Date:  2017-11-01       Impact factor: 18.302

9.  Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.

Authors:  Franziska S Thaler; Sarah A Laurent; Marion Huber; Matthias Mulazzani; Martin Dreyling; Uwe Ködel; Tania Kümpfel; Andreas Straube; Edgar Meinl; Louisa von Baumgarten
Journal:  Neuro Oncol       Date:  2017-11-29       Impact factor: 12.300

Review 10.  Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL.

Authors:  Alexander Baraniskin; Roland Schroers
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.